Biopsias líquidas en cáncer: ¿estamos preparados para remplazar el tejido tumoral?


  • Andrés F. Cardona Centro de Tratamiento e Investigación sobre Cáncer (CTIC)
  • Christian Rolfo Center for Thoracic Oncology
  • Umberto Malapelle Department of Human Pathology, University of Messina
  • Diego de Miguel-Pérez Center for Thoracic Oncology



The use of liquid biopsy (LB) has become highly relevant in the clinical field, and the acquisition of circulating free DNA (cfDNA) has become consolidated as an emerging biomarker and a tool for the research, diagnosis, and prognosis of solid tumors (1). Different studies have confirmed that this type of DNA contains information on specific tumor-related alterations, such as mutations, methylations, and copy number variants (CNVs) (2). The most striking advantage of LB is its ability to isolate ctDNA through a minimally invasive technique (1,3).


Biografía del autor/a

Andrés F. Cardona, Centro de Tratamiento e Investigación sobre Cáncer (CTIC)

Institute of Research, Science and Education, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center – CTIC, Bogotá, Colombia

Christian Rolfo, Center for Thoracic Oncology

Center for Thoracic Oncology, The Tisch Cancer Institute, Mount Sinai Health System and Icahn School of Medicine, New York, NY, United States

Umberto Malapelle, Department of Human Pathology, University of Messina

Medical Oncology Unit A.O. Papardo & Department of Human Pathology, University of Messina, Italy

Diego de Miguel-Pérez, Center for Thoracic Oncology

Center for Thoracic Oncology, The Tisch Cancer Institute, Mount Sinai Health System and Icahn School of Medicine, New York, NY, United States

Referencias bibliográficas

Aarthy R, Mani S, Velusami S, Sundarsingh S, Rajkumar T. Role of Circulating Cell-Free DNA in Cancers. Mol Diagn Ther. 2015;19(6):339-50. doi: 10.1007/ s40291-015-0167-y.

Hiley C, de Bruin EC, McGranahan N, Swanton C. Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine. Genome Biol. 2014;15(8):453. doi: 10.1186/ s13059-014-0453-8.

Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in earlyand late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24. doi: 10.1126/scitranslmed.3007094.

Bronkhorst AJ, Ungerer V, Holdenrieder S. The emerging role of cell-free DNA as a molecular marker for cancer management. Biomol Detect Quantif. 2019;17:100087. doi: 10.1016/j.bdq.2019.100087.

Loft M, To YH, Gibbs P, Tie J. Clinical application of circulating tumour DNA in colorectal cancer. Lancet Gastroenterol Hepatol. 2023;8(9):837-852. doi: 10.1016/S2468-1253(23)00146-2.

Sisodiya S, Kasherwal V, Khan A, Roy B, Goel A, Kumar S, et al. Liquid Biopsies: Emerging role and clinical applications in solid tumours. Transl Oncol. 2023;35:101716. doi: 10.1016/j.tranon.2023.101716.

Mathai RA, Vidya RVS, Reddy BS, Thomas L, Udupa K, Kolesar J, et al. Potential Utility of Liquid Biopsy as a Diagnostic and Prognostic Tool for the Assessment of Solid Tumors: Implications in the Precision Oncology. J Clin Med. 2019;8(3):373. doi: 10.3390/jcm8030373.

Arnedos M, Vicier C, Loi S, Lefebvre C, Michiels S, Bonnefoi H, et al. Precision medicine for metastatic breast cancer--limitations and solutions. Nat Rev Clin Oncol. 2015;12(12):693-704. doi: 10.1038/nrclinonc.2015.123.

Patel KM, Tsui DW. The translational potential of circulating tumour DNA in oncology. Clin Biochem. 2015;48(15):957-61. doi: 10.1016/j.clinbiochem.2015.04.005.

Dweh TJ, Pattnaik S, Sahoo JP. Assessing the impact of meta-genomic tools on current cutting-edge genome engineering and technology. Int J Biochem Mol Biol. 2023;14(4):62-75.

Nigro MC, Marchese PV, Deiana C, Casadio C, Galvani L, Di Federico A, et al. Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review. Lung Cancer (Auckl). 2023;14:11-25. doi: 10.2147/LCTT.S388047.

The ASCO Post. FDA Approves cobas EGFR Mutation Test v2 as Companion Diagnostic With Gefitinib in First-Line Treatment of NSCLC [Internet]. 2018 [Consultado junio 1 de 2019]. Disponible en:

Basnet S, Zhang Z-Y, Liao W-Q, Li S-H, Li P-S, Ge H-Y. The Prognostic Value of Circulating Cell-Free DNA in Colorectal Cancer: A Meta-Analysis. J Cancer. 2016;7(9):1105–13.

Hench IB, Hench J, Tolnay M. Liquid Biopsy in Clinical Management of Breast, Lung, and Colorectal Cancer. Front Med (Lausanne). 2018;5:9. doi: 10.3389/ fmed.2018.00009.

O’Leary B, Hrebien S, Morden JP, Beaney M, Fribbens C, Huang X, et al. Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. Nat Commun. 2018;9(1):896. doi: 10.1038/s41467-018-03215-x.

Yadav DK, Bai X, Yadav RK, Singh A, Li G, Ma T, et al. Liquid biopsy in pancreatic cancer: the beginning of a new era. Oncotarget. 2018;9(42):26900–33.

Shapiro B, Chakrabarty M, Cohn EM, Leon SA. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer. 1983;51(11):2116–20.

Tabernero J, Lenz H-J, Siena S, Sobrero A, Falcone A, Ychou M, et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol. 2015;16(8):937–48.

Tjensvoll K, Lapin M, Buhl T, Oltedal S, Steen-Ottosen Berry K, Gilje B, et al. Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer. Mol Oncol. 2016;10(4):635–43.

Cohen PA, Flowers N, Tong S, Hannan N, Pertile MD, Hui L. Abnormal plasma DNA profiles in early ovarian cancer using a non-invasive prenatal testing platform: implications for cancer screening. BMC Med. 2016;14(1):126.

Okajima W, Komatsu S, Ichikawa D, Miyamae M, Ohashi T, Imamura T, et al. Liquid biopsy in patients with hepatocellular carcinoma: Circulating tumor cells and cell-free nucleic acids. World J Gastroenterol. 2017;23(31):5650–68.

Payne K, Spruce R, Beggs A, Sharma N, Kong A, Martin T, et al. Circulating tumor DNA as a biomarker and liquid biopsy in head and neck squamous cell carcinoma. Head Neck. 2018;40(7):1598–604.

Bertero L, Siravegna G, Rudà R, Soffietti R, Bardelli A, Cassoni P. Review: Peering through a keyhole: liquid biopsy in primary and metastatic central nervous system tumours. Neuropathol Appl Neurobiol. 2019;45(7):655-670. doi: 10.1111/nan.12553.

Boire A, Brandsma D, Brastianos PK, Le Rhun E, Ahluwalia M, Junck L, et al. Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications. Neuro-oncology. 2019;21(5):571–84.

Cómo citar

F. Cardona, A. et al. 2023. Biopsias líquidas en cáncer: ¿estamos preparados para remplazar el tejido tumoral?. Medicina. 45, 4 (dic. 2023), 634–640. DOI:


Los datos de descargas todavía no están disponibles.



Crossref Cited-by logo